Showing results (41-50 of 336) with videos related to
Sort By:
Pageof 34
American Journal of Physiology. Heart and Circulatory Physiology|March 5, 2017
Psoriasis as a human model of disease to study inflammatory atherogenesisCharlotte L Harrington, Amit K Dey, Raza Yunus, et al.Journal of Translational Medicine|October 29, 2017
GlycA, a novel biomarker of systemic inflammation and cardiovascular disease riskMargery A Connelly, James D Otvos, Irina Shalaurova, et al.Frontiers in Immunology|October 29, 2020
T Cells in Autoimmunity-Associated Cardiovascular DiseasesDaniella Muallem Schwartz, Aarohan M Burma, Moses M Kitakule, et al.Immunology|September 8, 2011
The Toll-like receptor 1/2 agonists Pam(3) CSK(4) and human β-defensin-3 differentially induce interleukin-10 and nuclear factor-κB signalling patterns in human monocytesNicholas T Funderburg, Julie K Jadlowsky, Michael M Lederman, et al.Journal of Behavioral Medicine|January 16, 2022
Sexual minorities are at elevated risk of cardiovascular disease from a younger age than heterosexualsJessica Sherman, Christina Dyar, Jodi McDaniel, et al.Immunology|October 31, 2019
Highly oxidized low-density lipoprotein mediates activation of monocytes but does not confer interleukin-1β secretion nor interleukin-15 transpresentation functionScott F Sieg, Douglas A Bazdar, David Zidar, et al.The Journal of Rheumatology. Supplement|June 3, 2019
Cardiovascular Diseases in Psoriasis and Psoriatic ArthritisLihi Eder, Amit Dey, Aditya A Joshi, et al.Arthritis Research & Therapy|August 1, 2014
Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease InitiativeShawn Rose, Jenny Dave, Corina Millo, et al.Frontiers in Immunology|June 19, 2018
Potential Immunological Links Between Psoriasis and Cardiovascular DiseaseAparna P Sajja, Aditya A Joshi, Heather L Teague, et al.Pathogens & Immunity|August 9, 2016
Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but Does Not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral TherapyNicholas T Funderburg, Morgan Boucher, Abdus Sattar, et al.Pageof 34